Table 2 Correlation between various clinicopathological factors and recurrence in ER-positive DCIS treated with breast-conserving surgery.
From: The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ
Parameter | ER-positive DCIS in BCS-treated patients (n = 242) | ||
|---|---|---|---|
No recurrence (n = 190) | Recurrence (n = 52) | χ2 (P value) | |
Age (years)a | |||
 <40 | 3 (2) | 3 (6) | 2.979 (0.226) |
 40–60 | 101 (53) | 26 (50) | |
 >60 | 86 (45) | 23 (44) | |
Presentation | |||
 Screening | 121 (64) | 26 (50) | 3.206 (0.073) |
 Symptomatic | 69 (36) | 26 (50) | |
Sizea | |||
 <16 mm | 101 (53) | 28 (54) | 0.127 (0.966) |
 16–40 mm | 76 (40) | 20 (39) | |
 >40 mm | 13 (7) | 4 (7) | |
Grade | |||
 Low | 46 (24) | 4 (8) | 7.028 (0.030) |
 Intermediate | 61 (33) | 19 (36) | |
High | 82 (43) | 29 (56) | |
Comedo necrosis | |||
 Yes | 104 (55) | 24 (46) | 1.207 (0.272) |
 No | 86 (45) | 28 (54) | |
Radiotherapy | |||
 Yes | 68 (36) | 6 (12) | 11.311 (0.001) |
 No | 122 (64) | 46 (88) | |
Margin status (mm) | |||
 <2 | 9 (5) | 2 (4) | 0.058 (0.971) |
 ≥2 | 169 (95) | 44 (96) | |
PR status | |||
 Positive | 144 (83) | 38 (84) | 0.038 (0.846) |
 Negative | 29 (17) | 7 (16) | |
HER2 statusb | |||
 Negative | 125 (85) | 40 (84) | 0.011 (0.915) |
 Positive | 23 (15) | 7 (16) | |
